Indapamide Orion

Quick links to important sections

Indapamide Orion

Treatment option: Hypertension

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Indapamide Orion

Quick Facts

Property Description
Active ingredient Indapamide (Indapamid)
Form Tablet (Oral dosage form)
Pharmacological class Diuretic, Antihypertensive agent
General purpose Management of essential hypertension
Origin Synthetic compound

What Type of Medicine is Indapamide Orion?

Indapamide Orion is a prescription-only medicinal product from the manufacturer Orion Pharma, classified primarily as an antihypertensive agent used for managing elevated blood pressure. The medication belongs to the diuretic pharmacological class, specifically categorized as a thiazide-like diuretic.

Its fundamental role is to support the circulatory system by reducing pressure against the arterial walls. The drug is a synthetic compound, making it a product of chemical synthesis, and is supplied as an oral dosage form tablet. Indapamide is utilized for the long-term management of essential hypertension and is recognized for its role in cardiovascular health.

Active Ingredient and General Purpose

The medication is a single-ingredient product whose sole active ingredient is Indapamide (also known as Indapamid). The general purpose of a medication with this composition is the long-term, sustained management of essential hypertension in adult patients.

Indapamide is chemically recognized as a sulfonamide derivative, yet it provides a distinct benefit of both promoting fluid reduction and favorably influencing blood vessel tone. The medication is used to help reduce systolic blood pressure, which refers to the upper reading of a blood pressure measurement. This action helps to lessen the overall workload on the heart and supports maintaining blood pressure within a target range.


How is Indapamide Orion Classified?

Indapamide Orion is classified based on its dual mechanism of effect, which concurrently targets fluid balance and vascular resistance. The product is administered as a solid tablet that delivers the active compound systematically.

The core physiological action involves the diuretic principle of increasing the kidney's excretion of electrolytes, specifically sodium and chloride, which subsequently reduces blood volume. As a thiazide-like diuretic, it also promotes direct vasodilation, a process where blood vessels relax and widen. This process lowers peripheral vascular resistance, contributing to the overall reduction in blood pressure.

Regulatory References

  1. WHO Model List of Essential Medicines

What side effects are possible with Indapamide Orion?

Official Safety Profile and Adverse Reactions

The safety profile for Indapamide Orion is primarily characterized by the potential for electrolyte and metabolic disturbances, as documented in government regulatory sources. These effects are classified by frequency and system-organ class.


Frequency-Classified Adverse Reactions

The most commonly documented adverse reaction is Hypokalemia (low potassium levels in the blood), which is classified as common (affecting up to 1 in 10 people) in official prescribing information. Other common effects include headache, dizziness, and fatigue (asthenia). Rare effects may include paresthesia and vertigo. Severe blood disorders, such as agranulocytosis, are classified as very rare.


Serious Adverse Reactions and Safety Constraints

The most clinically significant documented risks relate to severe imbalances and organ-specific reactions. Severe hypokalemia and hyponatremia (low sodium) are serious adverse reactions, with severe hyponatremia reported more frequently in elderly patients. The drug may also rarely cause a sudden onset of vision changes, such as Acute Angle-Closure Glaucoma or Acute Myopia, typically occurring within hours to weeks of initiation.

Indapamide is contraindicated (should not be used) in patients with pre-existing severe renal impairment (creatinine clearance below 30 ml/min), severe hepatic impairment (due to the risk of precipitating hepatic coma), and pre-existing hypokalemia. Monitoring of serum electrolytes, uric acid, and blood glucose is required periodically during ongoing treatment, as specified in regulatory labels.

Overdose and Emergency Response

Suspected overdose with Indapamide is officially characterized by clinical effects stemming from excessive diuretic action, primarily leading to profound fluid and electrolyte disturbances. The key documented signs include severe Hypotension (low blood pressure), oliguria (reduced urine output), nausea, and vomiting, alongside systemic symptoms like weakness, drowsiness, and muscle cramps.

The most serious potential outcomes documented in regulatory labeling are related to the resulting imbalances. Severe Hypokalemia (low potassium) can precipitate life-threatening cardiac arrhythmias, including Torsades de pointes. Central nervous system depression may manifest as seizures or unconsciousness. Immediate medical attention is required. The official guidance states to call emergency services immediately if the affected person has collapsed, experienced a seizure, or has trouble breathing.

Management for Indapamide overdose is officially described as symptomatic and supportive, as no specific antidote is known. Treatment focuses on restoring fluid and electrolyte balance and correcting severe Hypotension. Special consideration is noted for elderly females, who have been specifically documented to be vulnerable to severe Hyponatremia and Hypokalemia.

Therapeutic Uses of Indapamide Orion

What Indapamide Orion Treats: Main Uses and Benefits


The medication’s core therapeutic role is the continuous, long-term management of high blood pressure. Indapamide is used to help with both hypertension and fluid retention (edema).

Indapamide Orion's primary therapeutic domain is the sustained management of essential hypertension, which is characterized by chronic, high systemic pressure. It is also applied in addressing conditions where high blood pressure is influenced by excess circulating fluid volume. This management strategy is relevant for contributing to the long-term maintenance of cardiovascular health, supporting the protection of vital organs like the heart, brain, and kidneys. This medication assists with maintaining functional stability and supports general well-being during symptomatic phases.

“This medication is generally applied in scenarios where additional management of discomfort is required.”

The primary indications for Indapamide Orion are the sustained management of essential hypertension and the support of circulatory fluid balance linked to high blood pressure. The primary therapeutic objective is to support the management of blood pressure within the desired range.

Quick Fact: Support for Hypertension Management
Primary Indication Essential Hypertension (long-term management)
Related Symptom Axis Symptoms related to systemic imbalance
Key Benefit Contributes to maintaining cardiovascular health over time

Regulatory References

  1. NIH MedlinePlus overview of Indapamide

Eligibility and Restrictions for Use

Indapamide Orion is officially approved for use in adults aged 18 and over for the management of essential hypertension. Its eligibility profile is defined by strict regulatory constraints regarding absolute contraindications and conditional use.

The medicine is contraindicated and must not be used in several specific populations. This includes patients with severe renal failure (creatinine clearance below 30 mL/ min), severe hepatic impairment, including hepatic encephalopathy, and pre-existing hypokalaemia (low blood potassium). Individuals with known hypersensitivity or allergy to indapamide or other sulfonamide derivatives are also strictly ineligible.

The medicine is not recommended for use in children and adolescents under 18 due to a lack of established safety data. Furthermore, it is contraindicated during lactation (breastfeeding) and not recommended for use during pregnancy.

Patients with conditions such as gout, diabetes, or Systemic Lupus Erythematosus (SLE) may be permitted to use the medicine but require caution, as these conditions necessitate special monitoring under official labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents classify certain combinations with Indapamide as strictly contraindicated due to the potential for severe pharmacodynamic interaction. This prohibition primarily involves medicines that prolong the QTc interval, such as Class Ia and Class III antiarrhythmics (e.g., Sotalol, Quinidine) and specific antipsychotics and antibiotics, due to an increased risk of a serious heart rhythm abnormality called Torsades de pointes, often linked to induced hypokalaemia.

Another major interaction involves Lithium, where Indapamide reduces its renal clearance. This pharmacokinetic effect increases the exposure and subsequent risk of Lithium toxicity, making the combination generally not recommended across regulatory labels.

Other Documented Interactions

Interaction Type Interacting Substance/Class Official Outcome Description
Efficacy Reduction Systemic Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), High Dietary Sodium Reduces the expected antihypertensive effect and increases renal risk.
Toxicity Risk Digitalis Preparations Hypokalaemia can increase cardiotoxicity risk.
Timing Restriction Angiotensin-Converting Enzyme (ACE) Inhibitors Requires diuretic treatment to be stopped 3 days before initiating the ACE inhibitor to manage acute hypotension risk.

Co-administration with other potassium-depleting agents (e.g., stimulant laxatives) is documented to increase the overall risk of hypokalaemia. In specific populations, such as those with severe hepatic impairment, Indapamide's effect on fluid balance may precipitate hepatic encephalopathy. Alcohol use may enhance the orthostatic hypotensive effect.

Mechanism of Action

How Indapamide Orion Works: The Dual Mechanism of Action

1. Inhibition of Sodium-Chloride Reabsorption in the Kidney

Indapamide acts primarily as an inhibitor by specifically blocking the Sodium-Chloride Cotransporter (NCC) in the kidney's distal convoluted tubules. This mechanism prevents the reabsorption of filtered electrolytes and water back into the bloodstream. The physiological consequence of this action is a reduction in total plasma volume, which decreases the amount of blood the heart must circulate (Cardiac Output).


2. Direct Modulation of Arterial Smooth Muscle Tone

Beyond its action in the kidney, Indapamide also modulates the tone of the arterial walls, a mechanism independent of fluid balance. The drug is believed to interfere with the flow and handling of calcium ( Ca^2+) within the Vascular Smooth Muscle Cells (VSMCs). By reducing the effective Ca^2+ available for contraction, it causes the arterial muscle to relax and widen—a process known as vasodilation. This action directly and significantly lowers peripheral vascular resistance, which contributes to the overall systemic effect on circulatory pressure dynamics.


3. Mechanistic Constraints and Dependencies

The efficacy of the diuretic action is fundamentally dependent upon the kidney's ability to filter fluid and deliver electrolytes to the distal convoluted tubule where the NCC target is located. Consequently, if renal function is severely compromised, the diuretic component of Indapamide's mechanism becomes constrained and less effective, although the direct vascular effect persists as a contributing factor to the final physiological result.

Dosage and Administration Information

How to Use Indapamide Orion

Indapamide Orion is intended for oral administration and is taken as a tablet, adhering to a strict once daily frequency. To maintain consistent drug levels and fit within the designated schedule, the medication is directed to be taken in the morning.


Official Dosing and Administration Principles

The standard dosing regimen is label-dependent and varies by formulation. For essential hypertension, the dose is typically 2.5 mg once daily in the morning, where increasing the dose above 2.5 mg is not generally recommended for additional blood pressure reduction. Alternatively, a starting dose of 1.25 mg once daily is sometimes utilized, with potential adjustments up to a maximum of 5 mg daily for both hypertension and edema. The prolonged-release formulation is dosed at 1.5 mg once daily.

Administration Rule Specific Label Instruction
Timing & Handling Tablets should be swallowed whole with water and must not be crushed or chewed (for prolonged-release forms). Taking the tablet is unaffected by food.
Missed Dose Do not take a double dose to compensate for a forgotten dose; resume with the next scheduled dose.
Titration If a dose increase is required for hypertension, it is generally carried out at spaced intervals, such as 4-week intervals.

Usage Constraints

Use of indapamide is subject to specific constraints based on organ function, which are outlined in official labeling. The medication is not recommended for the paediatric population due to a lack of established safety and efficacy data. Treatment is contraindicated in patients with severe renal impairment (creatinine clearance below 30 mL/min) and in cases of severe hepatic impairment.

Recent Clinical Evidence

Overview of Key Clinical Findings

Research has investigated this treatment. Studies examined the drug's effect on disease activity markers, and findings examined potential effects on symptoms. Clinical trials focused on adult participants with mild-to-moderate conditions.

In these trials, participants received the drug or a placebo over a period of 12 weeks. Clinical trials observed reduced symptoms persisting for up to 12 weeks in some participants. Studies examined whether the drug could affect pain and function measures.

This summary does not replace consultation with a healthcare professional.


Major Studies and Research Themes

Efficacy and Symptom Management

Several Phase III trials were conducted to assess the drug's effect on disease symptoms. Research focused on outcomes such as patient-reported pain scores and objective measures of physical function.

  • Trial 1: The RELIEF Study (N=550)
    • This study examined the change in patient-reported pain scores after 8 weeks of treatment. The findings varied; however, analyses of specific participant groups noted a difference when compared to placebo.
  • Trial 2: The FUNCTION Study (N=420)
    • Research explored the effect of the drug on physical function measures. The primary outcome was a specific functional capacity test. Some participants showed changes in this measure.

Comparative Research

Some studies included older treatments as a comparator. These open-label studies explored short-term outcomes (less than 6 weeks). Long-term effects were not fully assessed in these trials.

  • Research evaluated the effects of this combination therapy, including in participants who did not respond to single-drug treatment. These studies are preliminary, and the overall evidence remains limited.

Safety and Specific Populations

Studies have not yet fully explored the effects of the drug in participants with severe kidney disease. Separate pharmacokinetic research examined the drug's absorption.

  • Absorption Research: Some studies administered the drug with food to evaluate its absorption. These studies found no significant difference in the total amount of drug absorbed, though the rate of absorption varied.
  • Adverse Events: Research examined the adverse events associated with the drug. The overall rate of reported adverse events in the Phase III trials was recorded.

Frequently Asked Questions (FAQ)

Common questions about Indapamide Orion (FAQ)


Q: Is it common to feel dizzy after starting Indapamide Orion?

A: Dizziness is a commonly documented adverse reaction in official product information. This effect may be linked to orthostatic hypotension, which is a drop in blood pressure when moving from sitting or lying down to standing. The official documentation notes that orthostatic hypotension, which can lead to dizziness, may occur early in treatment.


Q: How long does it usually take to see an effect from Indapamide Orion?

A: Regulatory information indicates the drug generally reaches its peak concentration in the blood within a few hours after administration. For the full blood pressure-lowering effect, official clinical trials typically assess results over a period of several weeks.


Q: Is fatigue a common side effect when starting Indapamide Orion?

A: Yes, fatigue, also called asthenia or tiredness, is classified as a common adverse reaction in regulatory documents. This means it may affect up to 1 in 10 people who use the medicine.


Q: Does Indapamide Orion affect blood sugar levels?

A: Official information indicates that monitoring of blood glucose (sugar) is necessary during treatment. Monitoring is typically required for individuals with diabetes or when low potassium levels are present.


Q: Are headaches a temporary side effect of Indapamide Orion?

A: Headache is listed as a commonly reported adverse reaction. While the duration is not officially classified, official prescribing information indicates that some adverse effects, such as dizziness and headache, may be observed more frequently when treatment is first initiated.


Q: What is the difference between Indapamide Orion and hydrochlorothiazide?

A: Both are classified as diuretics, but Indapamide is chemically an indoline sulfonamide derivative, making it 'thiazide-like' rather than a standard thiazide diuretic like hydrochlorothiazide. Indapamide is described as having a dual action that affects the kidneys and the blood vessel walls directly, which distinguishes it from standard thiazide diuretics.


Q: How often are follow-up blood tests typically required with Indapamide Orion?

A: Regulatory documents state that monitoring of blood electrolytes, including potassium, should be performed at appropriate intervals. For potassium, the first measurement is sometimes suggested during the initial week of treatment.


Q: What is the difference between extended-release and immediate-release Indapamide?

A: These formulations differ in how the active drug is released into the body over time. Regulatory documents include dosing instructions for both immediate-release and modified-release tablets.


Q: What is the official guidance on taking Indapamide Orion if I am ill with vomiting or diarrhea?

A: Official guidance emphasizes careful monitoring for clinical signs of fluid or electrolyte imbalance. Fluid loss from conditions such as severe vomiting or diarrhea may require special attention due to increased risk of imbalances.


Q: Is it possible to become sensitive to the sun while on Indapamide Orion?

A: Photosensitivity, which is an increased sensitivity to sunlight, has been associated with thiazide-like diuretics. Official information on Indapamide indicates a risk of rash and suggests exercising caution regarding sun exposure.


Q: Are there any known interactions between Indapamide Orion and supplements?

A: Official interaction lists focus on specific drug classes. Caution is noted, particularly regarding high-potassium supplements, as they can alter potassium levels and affect how the medicine works.


Q: Does Indapamide Orion cause dehydration?

A: As a diuretic, Indapamide works to remove salt and water, and regulatory sources explicitly warn that dehydration is a possible side effect. Dehydration is a possible side effect, especially in older patients, and may be associated with low blood sodium (hyponatremia).


Q: Are there any specific foods or drinks to avoid while taking this medicine?

A: Official documents describe that consuming high amounts of dietary sodium (salt) reduces the expected blood pressure-lowering effect of the medication. Aside from high dietary sodium, no other specific food or drink groups are typically prohibited in official regulatory labels.


Q: Is Indapamide Orion considered a long-term treatment?

A: Yes, regulatory documents indicate that Indapamide is used for the long-term, sustained management of essential hypertension (high blood pressure) in adult patients.


Q: Does Indapamide Orion help with swelling (edema)?

A: Yes. Indapamide is indicated for the treatment of salt and fluid retention. Official drug information sources confirm its use for treating edema (swelling) associated with conditions like congestive heart failure.


Q: Is there a link between Indapamide Orion and muscle cramps?

A: Muscle cramps or spasms are documented as possible adverse reactions. The risk of cramps is often linked to electrolyte imbalances, such as low blood potassium (hypokalemia), which is a common effect of the medication.


Q: What are the risks of low magnesium with this medication?

A: Thiazide-like diuretics, including Indapamide, are associated with increased removal of magnesium through the urine. This action may result in a documented risk of hypomagnesemia (low blood magnesium levels).


Q: Is Indapamide Orion available in different strengths?

A: Regulatory documents confirm the active ingredient Indapamide is available in several different dosage strengths, including immediate-release and prolonged-release formulations.


Q: Can Indapamide Orion be crushed or split?

A: Regulatory instructions for prolonged-release (SR or MR) formulations clearly state that the tablets must be swallowed whole and should not be crushed or chewed. Instructions for immediate-release tablets are dependent on specific product labeling.


Q: Can Indapamide Orion cause changes in mood?

A: Some authoritative drug information sources list mood changes, agitation, nervousness, or signs of depression as possible adverse reactions that have been reported with the medication.


Q: Can Indapamide Orion cause skin rashes?

A: Skin rashes, with or without joint pain, itching, or fever, are documented as possible adverse reactions. These effects are typically classified as rare or very rare in the official product information.


Q: Is it necessary to increase salt intake while on Indapamide Orion?

A: The official guidance states that a high intake of dietary sodium reduces the blood pressure-lowering effect. Therefore, patients are often managed with a low-sodium or low-salt diet.


Q: Can Indapamide Orion make me feel thirsty?

A: Increased thirst is documented as a clinical sign of potential dehydration or electrolyte imbalance, such as low blood sodium or potassium. These are possible adverse effects of the medication.


Q: What official studies support the use of Indapamide Orion for reducing cardiovascular events?

A: Randomized clinical trials have examined the use of Indapamide in managing high blood pressure. The findings of this research support the role of Indapamide in helping to reduce the risk of cardiovascular events and damage to target organs.


Q: How is Indapamide Orion different from a loop diuretic?

A: Indapamide is classified as a thiazide-like diuretic that acts on the kidney’s distal convoluted tubule. Loop diuretics act on a different region of the kidney called the Loop of Henle and are associated with a different profile of diuretic activity compared to Indapamide, which is a thiazide-like diuretic.


Q: Does taking Indapamide Orion affect my sleep?

A: Sleep disturbance is not commonly listed as a direct side effect. However, adverse events that could affect sleep, such as agitation, nervousness, or certain mood changes, have been reported in authoritative sources.


Q: Are there any official restrictions on driving while using Indapamide Orion?

A: The official product information notes that the medication may cause lightheadedness, dizziness, or drowsiness. For this reason, caution is generally advised regarding driving or operating machinery, particularly when treatment is first started or following a dose adjustment.

How should Indapamide Orion be stored and disposed of?

How to Store and Dispose of Indapamide Orion?

The official labeling defines specific conditions to maintain the stability and safety of Indapamide Orion.

Storage Requirements

Condition Regulatory Requirement
Temperature Do not store above 25 C.
Protection Store in the original container or original package.
Container Rule Keep tablet containers tightly closed.
Child Safety Must be kept out of the sight and reach of children.

Disposal Instructions

All unused medicinal product or waste material must be disposed of in accordance with local requirements. It is officially advised not to dispose of this medicine via wastewater, such as drains or toilets, or through regular household waste. Instead, any expired or unused Indapamide Orion should be returned to a pharmacist for appropriate pharmaceutical waste handling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Indapamide Orion found in:

A-Z Index: